RBC Capital Maintains a Buy on Natera (NTRA) With a $251 PT

Natera, Inc. (NASDAQ:NTRA) is one of the best strong buy healthcare stocks to buy now. On June 30, RBC Capital analyst Conor McNamara maintained a Buy rating on Natera, Inc. (NASDAQ:NTRA) and set a price target of $251.00.

Natera, Inc. (NASDAQ:NTRA) reported a 36.5% increase in total revenue in fiscal Q1 2025 to $501.8 million, compared to $367.7 million in Q1 2024. Management attributed this growth to a 37.1% increase in product revenues, which reached $500.0 million in Q1 2025 compared to $364.7 million in the same quarter last year.

Growth in product revenues was primarily driven by a rise in volume and average selling price improvements, along with cash receipts collected during Q1 in excess of initial revenue estimates for tests delivered in previous quarters.

Natera, Inc. (NASDAQ:NTRA) is a diagnostics company that develops and commercializes molecular testing services, applying its technological services in oncology, women’s health, and organ health.

The company provides various diagnostic tests, including Panorama non-invasive prenatal test (NIPT), Vistara, Horizon carrier screening (HCS), Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis, Anora products of conception (POC), and non-invasive paternity testing (PAT).

While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.